Study Graphic

The Pfizer New Haven Clinical Research Unit is conducting a study of a new investigational drug being studied to treat people with moderate to severe atopic dermatitis (AD). AD is a form of eczema (itchy, inflamed skin rash). The dose of the study drug to be used to treat people has not yet been determined. Study drug will be given as tablets, which you will swallow. Probenecid will also be given in this study. Probenecid is a marketed drug used to treat people with gout and gouty arthritis.

You may be eligible if:

  • You are a healthy male or female 18-55 years of age.
  • You are able to meet all eligibility criteria.
  • You are able to comply with all study visits.

Study Number: B7451043

Be compensated for your time: $3150.00 for completion of the study


This study involves:

You will be in this study up to about 46 days. This does not include the time between screening and dosing, which can be up to 28 days.

 This study involves:

3 dosing periods (during one continuous admission)

11 overnight stays

1 follow-up phone call between 28 and 35 days after the last dose of study drug

There will be at least 2 days between the dose of study drug in Period 1 and the first dose in Period 2, and at least 2 days between the last dose of study drug in Period 2 and the first dose of probenecid in Period 3.

Please review the Guidelines: B7451043 final Guidelines-Restriction-Dates v30Apr2019